Difference between revisions of "Vinblastine (Velban)"

Revision as of 00:37, 6 June 2023

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.^[1]^[2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Patient drug information

Diseases for which it is used

Diseases for which it was used

History of changes in FDA indication

1965-11-25: Initial approval
Uncertain date: Approved for generalized Hodgkin's disease (Stages III and IV, Ann Arbor modification of Rye staging system). (No supporting studies are cited)
Uncertain date: Approved for lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated). (No supporting studies are cited)
Uncertain date: Approved for histiocytic lymphoma. (No supporting studies are cited)
Uncertain date: Approved for mycosis fungoides (advanced stages). (No supporting studies are cited)
Uncertain date: Approved for advanced carcinoma of the testis. (Based on Loehrer et al. 1988)
Uncertain date: Approved for Kaposi's sarcoma. (No supporting studies are cited)
Uncertain date: Approved for Letterer-Siwe disease (histiocytosis X). (No supporting studies are cited)
Uncertain date: Approved for choriocarcinoma resistant to other chemotherapeutic agents. (No supporting studies are cited)
Uncertain date: Approved for carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy. (No supporting studies are cited)

Also known as

Generic names: chlorhexamide, vinblastine sulfate, vinblastine sulphate, vincaleukoblastine, VLB
Brand names:

Synonyms
Alkaban-AQ	Blastovin	Cellblastin	Cytoblastine	Erbablas
Exal	Faulblastina	Lemblastine	Periblastine	Rabinefil
Velban	Velbastine	Velbe	Vinblasin	Vinblastin
Vinblastina

References

[insert-1] 1.0 ^1.1 Vinblastine (Velban) package insert

[2] Vinblastine (Velban) package insert (locally hosted backup)

[3] Vinblastine (Velban) patient drug information (Chemocare)

[4] Vinblastine (Velban) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 35: / Line 35: @@
 *1965-11-25: Initial approval
 *Uncertain date: Approved for generalized [[Hodgkin lymphoma|Hodgkin's disease]] (Stages III and IV, Ann Arbor modification of Rye staging system). ''(No supporting studies are cited)''
-*Uncertain date: Approved for [[:Category:Non-Hodgkin lymphoma|lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated)]]. ''(No supporting studies are cited)''
+*Uncertain date: Approved for [[:Category:Non-Hodgkin lymphomas|lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated)]]. ''(No supporting studies are cited)''
-*Uncertain date: Approved for histiocytic lymphoma. ''(No supporting studies are cited)''
+*Uncertain date: Approved for [[Diffuse large B-cell lymphoma|histiocytic lymphoma]]. ''(No supporting studies are cited)''
 *Uncertain date: Approved for [[cutaneous T-cell lymphoma|mycosis fungoides]] (advanced stages). ''(No supporting studies are cited)''
 *Uncertain date: Approved for [[testicular cancer|advanced carcinoma of the testis]]. ''(Based on Loehrer et al. 1988)''